Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

Tseng, Hung Fu; Ackerson, Bradley K.; Luo, Yi; Sy, Lina S.; Talarico, Carla; Tian, Yun; Bruxvoort, Katia; Tubert, Julia E.; Florea, Ana; Ku, Jennifer H; Lee, Gina S.; Choi, Soon Kyu; Takhar, Harpreet S.; Aragones, Michael; Qian, Lei

doi:10.1038/s41591-022-01753-y

articleNature MedicineFeb 21, 2022HYBRID OA

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants

HFHung Fu Tseng BKBradley K. Ackerson YLYi Luo LSLina S. Sy CTCarla Talarico

Kaiser Permanente · Moderna Therapeutics (United States) · +1 more institution

PubMed

Indexed incrossrefpubmed

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant is highly transmissible with potential immune escape. We conducted a test-negative case-control study to evaluate mRNA-1273 vaccine effectiveness (VE) against infection and hospitalization with Omicron or Delta. The large, diverse study population included 26,683 SARS-CoV-2 test-positive cases with variants determined by S gene target failure status (16% Delta and 84% Omicron). The two-dose VE against Omicron infection at 14-90 days was 44.0% (95% confidence interval, 35.1-51.6%) but declined quickly. The three-dose VE was 93.7% (92.2-94.9%) and 86.0% (78.1-91.1%) against Delta infection and 71.6% (69.7-73.4%) and 47.4%…

Citation impact

555

total citations

FWCI: 55.14
Percentile: 100%
References: 24

Citations per year

Authors

15

Topics & keywords

Topics

Keywords

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Coronavirus disease 2019 (COVID-19)
Population
Medicine
Confidence interval
Virology
2019-20 coronavirus outbreak
Internal medicine

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.